Fesnak, A T Cell and Related Immunotherapies , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024

Fesnak, A Gene Therapy , Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: 2024

Mack EA, Dougher MC, Ginda AM, Cahill C, Murter M, Schell K, Tanhehco YC, Bhoj VG, Fesnak AD, Siegel DL, Kambayashi T, Aqui NA, O'Doherty U Red cell exchange for rapid leukoreduction in adults with hyperleukocytosis and leukostasis , Blood, 143(11): 2024,1049-1054

Wang K, Tseng CY, Li Z, White C, Wang B, Levine BL, Fesnak AD A simulation-based comparison of centralized and point-of-care supply chain strategies for autologous cell therapy , Cytotherapy, 25(12): 2023,1370-1379

Plesa G, Brennan AL, Levine JR, Hasenmayer D, Buchholz K, Migliaccio T, Holland D, Colligon TA, Mackey S, Dai A, Petrella J, Ngo S, Fesnak A, Davis MM, Siegel D Multiple Efficiencies Gained by Implementing a Significantly Shorter Manufacturing Schedule for Production of CAR T Cell Products , Cytotherapy, 25(6): 2023,S9

Mackey, S., Dai, A., Gong, N., McGettigan, B., Jefferson, P., Petrella, J., Gohil, M., Fesnak, A., Siegel, D., Davis, M. M., Plesa, G. Developing and Optimizing Multicolor Flow Cytometry Methods for the Manufacturing and Release of 3-Day HuCART Products , Cytotherapy, 25(6): 2023,S189-S190

Fesnak AD, Raval JS Adverse Events of Cellular and Biotherapies , AABB Technical Manual, 21st edition: 2023

Fesnak AD, Siegel DL Chimeric antigen receptor T cells and other cellular immunotherapies , Rossi's Principles of Transfusion Medicine, Sixth Edition: 2022

Guleria I, de Los Angeles Muñiz M, Wilgo M, Bapat A, Cui W, Hsu YS, Jeyaraman M, Muthu S, Rodriguez F, Fesnak A, Celluzzi C, Sesok-Pizzini D, Reich-Slotky R, Spitzer T. How do I: Evaluate the safety and legitimacy of unproven cellular therapies? , Transfusion, 62(3): 2022,518-532

Frey NV, Gill S, Hwang WT, Luger SM, Martin ME, McCurdy, SR, Loren AW, Pratz KW, Perl AE, Barber-Rotenberg J, Marshall A, Ruella M, Lacey SF, Fraietta J, Fesnak A, O'brien M, Schanne T, Brogdon JL, Engels B, Levine BL, June CH, Porter DL, Hexner EO CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL , Blood, 138(Supplement 1): 2021,469